Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on developing and providing therapies for patients with hematologic disorders and cancer in the United States. Its commercial products include TAVALISSE, an oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia in adults; REZLIDHIA, a non-intensive monotherapy for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation; and GAVRETO, a kinase inhibitor for RET fusion-positive non-small cell lung cancer and thyroid cancer. The company also has a pipeline candidate, R289, an oral IRAK1/4 inhibitor being studied for hematology-oncology and inflammatory diseases, including lower-risk myelodysplastic syndrome. Additionally, Rigel collaborates with MD Anderson Cancer Center and the CONNECT network to advance olutasidenib in IDH1-mutated cancers.

Rigel Pharmaceuticals, Inc. is listed on the Nasdaq Global Select Market under the ticker symbol RIGL. Its shares trade in U.S. dollars (USD). The exchange is part of the Nasdaq stock exchange, which is one of the major electronic exchanges in the United States. Investors can buy and sell RIGL shares during regular trading hours on NasdaqGS.

Rigel Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing therapies for serious diseases, primarily in hematology and oncology. The company's work involves targeted small-molecule inhibitors that modulate specific pathways involved in disease, such as spleen tyrosine kinase (SYK), isocitrate dehydrogenase-1 (IDH1), and rearranged during transfection (RET) kinases. This places Rigel among other biotech firms that aim to address unmet medical needs through innovative drug development.

Rigel Pharmaceuticals is headquartered in the United States and primarily serves the U.S. market. The company's description indicates that it develops and provides therapies for patients with hematologic disorders and cancer in the United States. While its headquarters location is not explicitly stated in the provided data, its country is listed as the United States and its region as 'us'. Rigel's commercial products, such as TAVALISSE, REZLIDHIA, and GAVRETO, are approved by the U.S. Food and Drug Administration (FDA) and marketed domestically. The company also engages in research collaborations with U.S. institutions like MD Anderson Cancer Center and the CONNECT network, further emphasizing its focus on the American healthcare system.

Rigel Pharmaceuticals has three main commercial products. TAVALISSE (fostamatinib) is an oral spleen tyrosine kinase inhibitor approved for adult patients with chronic immune thrombocytopenia, a bleeding disorder. REZLIDHIA (olutasidenib) is a non-intensive monotherapy for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. GAVRETO (pralsetinib) is a once-daily oral kinase inhibitor for adult patients with metastatic RET fusion-positive non-small cell lung cancer and for adult and pediatric patients 12+ with advanced or metastatic RET fusion-positive thyroid cancer. Additionally, Rigel is developing R289, an oral IRAK1/4 inhibitor, currently in Phase 1b studies for lower-risk myelodysplastic syndrome and other indications. The company also collaborates on olutasidenib in other IDH1-mutated cancers.